14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
INBX vs KYMR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). INBX carries a Unified Composite Score of 51.4/100 (HOLD) at $77.32 (N/M Forward P/E, 0.0% operating margin), whereas KYMR carries 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin).
Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (51.4/100 HOLD vs. KYMR 47.1/100 HOLD), KYMR captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-396.0% vs. 0.0% operating margin) and revenue trajectory (+466.4% vs. -100.0% YoY).
Technical & Structure Timing Caution: INBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6); meanwhile KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $10.9B market capitalization and -396.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ INBX vs KYMR Key Questions & Quantitative Answers
As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). INBX carries a Unified Composite Score of 51.4/100 (HOLD) at $77.32 (N/M Forward P/E, 0.0% operating margin), whereas KYMR carries 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin). Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (51.4/100 HOLD vs. KYMR 47.1/100 HOLD), KYMR captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-396.0% vs. 0.0% operating margin) and revenue trajectory (+466.4% vs. -100.0% YoY). Technical & Structure Timing Caution: INBX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6); meanwhile KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KYMR leads the Growth & Scale pillar: INBX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with KYMR at +466.4% YoY revenue growth and +0.0% YoY earnings growth on $102M TTM revenue (N/A gross margin, -396.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), INBX cumulative revenue shifted N/A while KYMR shifted +33.3%. In operating R&D and SG&A reinvestment, INBX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KYMR.
KYMR screens cheaper on headline valuation multiples. INBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas KYMR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INBX (-1773.6% ROE) versus KYMR (-27.3% ROE) capital efficiency.
In options market volatility and institutional positioning, INBX carries 116.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.53β · 120% Vol realized risk). By comparison, KYMR carries 129.6% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.